“I think that if you look at across all three, all three patient groups... math will work out to what you just kind of highlighted there. In the kind of low teens.”

In context

“next year, you mean 2026. Right? Robbie Marcus: Yes. Thank you. Robert Ford: Got it. Yeah. Yeah. I mean, I think yeah. There's all this debate that I read about that the market's slowing, and I get if you're just looking at percentages and that's how you base yourself off it, then I guess if it's that myopic, then I think okay. I understand the conclusion. But I don't consider growing a billion dollars every single year and doing it four years in a row to be slowing down here, Robbie. I think the math will work out to what you just kind of highlighted there. In the kind of low teens. But I think there's still a lot of opportunity for penetration in this both from a market perspective, but then also from our opportunity, you know, our ability to drive market share in and market expansion. I think that if you look at across all three, all three patient groups, whether it's the intensive insulin user, you know, the basal insulin user, and the non-insulin user, all of those areas still there's so much penetration to be able to have here. And you can see across the world, not just in The United States but across the world, you know, a lot of movement whether it's patient groups, healthcare systems that are, you know, looking to expand the use and the adoption of the technology into all these patient segments. You know, The US gets a lot of attention and it's an important market and, you know, there's a lot of great opportunities for us there in terms of the non-insulin user reimbursement opportunity. I continue to see nice progress in this process. Seems to be a lot of support to do this. And the data that we've shown, like we've published three studies already that show that this patient segment also benefits with lower A1c, greater ti”